Table 1.
Influence of dapagliflozin on clinical parameters in newly diagnosed T2D patients
| Characteristic | Baseline | After treatment | p value |
|---|---|---|---|
| Age,y | 47.5 ± 12.6 | ||
| Gender, F/M, n | 28/29 | ||
| BMI, kg/m2 | 28.17 ± 2.70 | 26.57 ± 3.33 | 0.000 |
| TG, mmol/L | 1.75 (1.32–2.29) | 1.48 (1.12–2.22) | 0.083 |
| TC, mmol/L | 5.21 ± 1.04 | 5.10 ± 0.94 | 0.296 |
| HDL-C, mmol/L | 1.15 ± 0.27 | 1.18 ± 0.30 | 0.122 |
| LDL-C, mmol/L | 3.56 ± 1.02 | 3.43 ± 0.95 | 0.222 |
| NEFA, mmol/L | 0.71 ± 0.21 | 0.75 ± 0.22 | 0.199 |
| FBG, mmol/L | 8.78 ± 1.78 | 6.33 ± 0.91 | 0.000 |
| FINS, mIU/L | 11.60 (8.40–17.00) | 9.60(6.65–14.92) | 0.026 |
| HOMA-IR | 4.34 (2.97–6.43) | 2.89 (1.75–4.14) | 0.000 |
| HbA1c, % | 8.38 ± 1.05 | 6.59 ± 0.55 | 0.000 |
| CREA, mmol/L | 60.43 ± 11.66 | 61.77 ± 11.51 | 0.098 |
| eGFR, mL/min/1.73m2 | 111.30 ± 10.51 | 109.91 ± 11.01 | 0.028 |
Data are mean ± standard deviation unless indicated otherwise. TG, FINS, and HOMA-IR are shown as medians, the upper and lower quartiles
T2D: type 2 diabetes; BMI: body mass index; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NEFA: Nonesterified fatty acid; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: hemoglobin A1c; CREA: creatinine; eGFR: estimated glomerular filtration rate